| 查看: 364 | 回复: 0 | |||
| 当前主题已经存档。 | |||
chendexin木虫 (正式写手)
|
[交流]
Drug lifts blindness threat for thousands
|
||
|
By Nigel Hawkes, Health Editor Click here for graphic A CONDITION that causes thousands of Britons to go blind every year can be halted and even reversed with a monthly injection. Trials into a treatment for age-related macular degeneration (AMD), which is diagnosed in more than 20,000 elderly people a year and is the commonest cause of blindness, have shown dramatic results for almost all who use it. Patients given Lucentis did not only have the gradual deterioration of their sight halted, but even regained vision lost to the disease. For decades, patients with the condition, which leaves 10 per cent of sufferers blind, have been told there is little or nothing that can be done to slow the disease, let alone reverse it. But in a new trial Lucentis reversed sight damage in more than a third of participants with “wet” AMD, the most damaging form of the disease. It also prevented further loss of vision in almost all who were treated with it. About 24,000 patients a year have wet AMD diagnosed. It is responsible for 90 per cent of cases where people lose their sight entirely: loss of vision is caused by the growth of new blood vessels behind the retina, which cause bleeding and scarring. Lucentis, developed by the Californian company Genentech, does not yet have a British licence. At £1,000 a treatment, it will raise serious funding questions for the NHS if recommended for use by the National Institute for Health and Clinical Excellence (NICE), which is conducting an appraisal. Costs for treating all newly diagnosed cases to a course of monthly injections — the regime used in the trial — are put at £400 million. Steve Winyard, head of campaigns at the Royal National Institute of the Blind, said that the results were very exciting. “These results show that the drug is just as good as we thought it was going to be. About 30 per cent of these patients got a significant gain in sight, which shows that the drug also offers improvements as well as preventing sight loss.” John Blake, 75, one of the few patients in Britain to have been treated with Lucentis, said that the drug had improved his sight sufficiently for him to be able to take up golf again. “Everything had gone, 80 per cent of my life had gone”, he said. “I couldn’t drive or watch TV,” he said. “Within three days my sight had improved. It cost me nearly £5,000, but I’m very pleased.” The two trials published today in The New England Journal of Medicine compared Lucentis with a placebo and Visudyne, the only treatment hitherto available on the NHS. In the placebo-controlled trial, 716 US patients were randomly given Lucentis at two dose levels, or a placebo. Over two years, a third of patients given the higher dose of Lucentis gained in visual acuity, compared with only 4 per cent given the placebo. On average, Lucentis patients were able to read about six more letters on the optician’s chart after two years of treatment than at the start, while those given a placebo could read fifteen fewer letters. In the second trial, Lucentis was compared with Visudyne. Over two years, between 35 and 40 per cent of those given Lucentis improved by an average of 15 letters, while fewer than 6 per cent of the Visudyne group did this well. Yit Yang, a consultant ophthalmologist from Wolverhampton, described the results as very striking. “These results mean that potentially people with wet AMD can become independent again and return to activities such as reading, shopping and hobbies.” By Nigel Hawkes, Health Editor Click here for graphic A CONDITION that causes thousands of Britons to go blind every year can be halted and even reversed with a monthly injection. Trials into a treatment for age-related macular degeneration (AMD), which is diagnosed in more than 20,000 elderly people a year and is the commonest cause of blindness, have shown dramatic results for almost all who use it. Patients given Lucentis did not only have the gradual deterioration of their sight halted, but even regained vision lost to the disease. For decades, patients with the condition, which leaves 10 per cent of sufferers blind, have been told there is little or nothing that can be done to slow the disease, let alone reverse it. But in a new trial Lucentis reversed sight damage in more than a third of participants with “wet” AMD, the most damaging form of the disease. It also prevented further loss of vision in almost all who were treated with it. About 24,000 patients a year have wet AMD diagnosed. It is responsible for 90 per cent of cases where people lose their sight entirely: loss of vision is caused by the growth of new blood vessels behind the retina, which cause bleeding and scarring. Lucentis, developed by the Californian company Genentech, does not yet have a British licence. At £1,000 a treatment, it will raise serious funding questions for the NHS if recommended for use by the National Institute for Health and Clinical Excellence (NICE), which is conducting an appraisal. Costs for treating all newly diagnosed cases to a course of monthly injections — the regime used in the trial — are put at £400 million. Steve Winyard, head of campaigns at the Royal National Institute of the Blind, said that the results were very exciting. “These results show that the drug is just as good as we thought it was going to be. About 30 per cent of these patients got a significant gain in sight, which shows that the drug also offers improvements as well as preventing sight loss.” John Blake, 75, one of the few patients in Britain to have been treated with Lucentis, said that the drug had improved his sight sufficiently for him to be able to take up golf again. “Everything had gone, 80 per cent of my life had gone”, he said. “I couldn’t drive or watch TV,” he said. “Within three days my sight had improved. It cost me nearly £5,000, but I’m very pleased.” The two trials published today in The New England Journal of Medicine compared Lucentis with a placebo and Visudyne, the only treatment hitherto available on the NHS. In the placebo-controlled trial, 716 US patients were randomly given Lucentis at two dose levels, or a placebo. Over two years, a third of patients given the higher dose of Lucentis gained in visual acuity, compared with only 4 per cent given the placebo. On average, Lucentis patients were able to read about six more letters on the optician’s chart after two years of treatment than at the start, while those given a placebo could read fifteen fewer letters. In the second trial, Lucentis was compared with Visudyne. Over two years, between 35 and 40 per cent of those given Lucentis improved by an average of 15 letters, while fewer than 6 per cent of the Visudyne group did this well. Yit Yang, a consultant ophthalmologist from Wolverhampton, described the results as very striking. “These results mean that potentially people with wet AMD can become independent again and return to activities such as reading, shopping and hobbies.” 学习 交流 阅读 欣赏 翻译 提高 了解最新信息 |
回复此楼» 猜你喜欢
基金申报
已经有5人回复
-
基金委咋了？2026年的指南还没有出来？
已经有7人回复
-
国自然申请面上模板最新2026版出了吗？
已经有17人回复
-
纳米粒子粒径的测量
已经有8人回复
-
疑惑？
已经有5人回复
-
计算机、0854电子信息（085401-058412）调剂
已经有5人回复
-
Materials Today Chemistry审稿周期
已经有5人回复
-
溴的反应液脱色
已经有7人回复
-
推荐一本书
已经有12人回复
-
常年博士招收(双一流，工科)
已经有4人回复